Catalent Inc (CTLT) Expected to Post Earnings of $0.38 Per Share
Analysts predict that Catalent Inc (NYSE:CTLT) will post earnings of $0.38 per share for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Catalent’s earnings. The highest EPS estimate is $0.45 and the lowest is $0.34. Catalent posted earnings per share of $0.45 during the same quarter last year, which would indicate a negative year over year growth rate of 15.6%. The company is expected to announce its next earnings results on Monday, February 4th.
On average, analysts expect that Catalent will report full year earnings of $1.82 per share for the current fiscal year, with EPS estimates ranging from $1.74 to $1.90. For the next financial year, analysts anticipate that the firm will post earnings of $1.99 per share, with EPS estimates ranging from $1.84 to $2.17. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Catalent.
Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 6th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.04. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The firm had revenue of $551.80 million during the quarter, compared to analysts’ expectations of $582.44 million. During the same period in the prior year, the company earned $0.21 earnings per share. The company’s quarterly revenue was up 1.5% on a year-over-year basis.
In related news, insider John R. Chiminski sold 130,545 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $45.32, for a total value of $5,916,299.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Lance Miyamoto sold 6,525 shares of the stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $42.50, for a total value of $277,312.50. The disclosure for this sale can be found here. Insiders sold 184,335 shares of company stock valued at $8,161,727 over the last 90 days. 1.40% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Seven Eight Capital LP acquired a new stake in Catalent in the third quarter valued at $506,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Catalent during the 2nd quarter worth about $1,508,000. Millennium Management LLC grew its holdings in Catalent by 4,244.2% during the 2nd quarter. Millennium Management LLC now owns 1,200,267 shares of the company’s stock worth $50,279,000 after acquiring an additional 1,172,638 shares during the period. Aperio Group LLC grew its holdings in Catalent by 7.0% during the 3rd quarter. Aperio Group LLC now owns 33,563 shares of the company’s stock worth $1,529,000 after acquiring an additional 2,185 shares during the period. Finally, Tibra Equities Europe Ltd acquired a new stake in Catalent during the 2nd quarter worth about $6,653,000. Institutional investors and hedge funds own 96.77% of the company’s stock.
NYSE CTLT traded down $2.22 on Friday, hitting $38.07. 698,828 shares of the company’s stock were exchanged, compared to its average volume of 1,161,373. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.61. Catalent has a 52 week low of $34.24 and a 52 week high of $47.87. The stock has a market capitalization of $5.76 billion, a PE ratio of 23.94, a PEG ratio of 2.52 and a beta of 1.44.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Story: Benefits of owning preferred stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.